RTP Mobile Logo
Oncology Today with Dr Neil Love: Special Edition — Key Presentations on Chronic Lymphocytic Leukemia and Lymphoma from Recent Major Oncology/Hematology Conferences (Audio Interview)
Released August 2023

Featuring an interview with Dr Jeremy Abramson. Published August 28, 2023. (Audio Interview)

CE Information and Faculty Disclosures

  • TARGET AUDIENCE
    This program is intended for medical oncologists, hematologists, hematology-oncology fellows, radiation oncologists and other allied healthcare professionals involved in the treatment of chronic lymphocytic leukemia and lymphoma.

    LEARNING OBJECTIVES

    • Individualize the selection and sequencing of systemic therapy for patients with newly diagnosed or relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) or lymphomas, considering patient- and disease-specific factors.
    • Understand published research data informing the selection, sequencing or combining of available therapeutic agents in the nonresearch care of patients with previously untreated or R/R CLL.
    • Recognize the mechanisms of action, efficacy and safety of approved and investigational bispecific antibodies in the treatment of R/R diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL).
    • Assess available clinical trial findings supporting CD19-directed CAR (chimeric antigen receptor) T-cell therapy for R/R DLBCL, mantle cell lymphoma (MCL), FL and CLL, and counsel appropriately selected patients about the potential benefits of this strategy.
    • Incorporate available and emerging therapeutic strategies into the best-practice management of MCL and Hodgkin lymphoma.
    • Recall new data with agents and strategies currently under investigation for CLL and various lymphoma subtypes, and discuss ongoing trial opportunities with eligible patients.

    ACCREDITATION STATEMENT
    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CREDIT DESIGNATION STATEMENT
    CME credit is no longer available for this issue

    AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
    CME credit is no longer available for this issue

    PRIVACY POLICY
    Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

    HOW TO USE THIS CME ACTIVITY
    Audio Program: This CME activity consists of an audio component.
    CME credit is no longer available for this issue

    Video Program: This CME activity consists of a video component.
    CME credit is no longer available for this issue

    Presentations Program: This CME activity consists of a video component.
    CME credit is no longer available for this issue

    CONTENT VALIDATION AND DISCLOSURES
    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

    Jeremy S Abramson, MD, MMSc
    Director, Center for Lymphoma
    Massachusetts General Hospital
    Associate Professor of Medicine
    Harvard Medical School
    Boston, Massachusetts

    Consulting Agreements: AbbVie Inc, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Bristol Myers Squibb, Caribou Biosciences Inc, Cellectar Biosciences Inc, Century Therapeutics, Epizyme Inc, Genentech, a member of the Roche Group, Genmab US Inc, Incyte Corporation, Interius BioTherapeutics, Janssen Biotech Inc, Kite, A Gilead Company, Lilly, Regeneron Pharmaceuticals Inc, Takeda Pharmaceuticals USA Inc; Contracted Research: Bristol Myers Squibb, Cellectis, Merck, Mustang Bio, Seagen Inc.

    EDITOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab US Inc, Gilead Sciences Inc, Grail Inc, GSK, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Kronos Bio Inc, Legend Biotech, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc, and Zymeworks Inc.

    RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    These educational activities contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    These activities are supported by educational grants from AbbVie Inc, ADC Therapeutics, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Bristol Myers Squibb, and Lilly.

    Release date: August 2023
    Expiration date: August 2024

Acknowledge and close

Listen to audio
(WIFI is recommended for best performance):